J&J slashes third-quarter profit by $3 billion over proposed opioid deal
Reuters
Published Oct 23, 2019 07:10PM ET
J&J slashes third-quarter profit by $3 billion over proposed opioid deal
(Reuters) - Johnson & Johnson (N:JNJ) on Wednesday lowered its previously reported third-quarter profit by $3 billion to account for a proposed opioid settlement payment.
A framework settlement, announced on Monday, was hammered out by some drugmakers and distributors and attorneys general in North Carolina, Pennsylvania, Tennessee and Texas. The proposed deal will need broad support among all the state attorneys general and local governments that have sued the companies over the opioid crisis.
J&J, which is facing thousands of lawsuits over a variety of products, lowered its reported profit to $1.8 billion, or 66 cents per share, from $4.8 billion, or $1.81 per share, and said there was no impact to its adjusted earnings numbers.
The company said it could not predict when or if the opioid deal would be finalized.
"(J&J) has to disclose it now - and take the accounting hit. Later they can come back and adjust the impact on an actual payment/settlement on their goodwill when the actual cost of the settlement comes into focus," Brian Quinn at Boston College Law School said.
Reuters reported last week citing sources that drug distributors McKesson Corp (N:MCK), AmerisourceBergen Corp (N:ABC) and Cardinal Health (N:CAH) have offered to pay $18 billion in cash over 18 years, while drugmaker Johnson & Johnson (N:JNJ) would pay $4 billion in cash.
The drug industry faces roughly 2,600 lawsuits brought by state and local governments, hospitals and other entities seeking to hold drugmakers and distributors responsible for the toll of opioid abuse.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.